Fungi · Scientific monograph
Coprinus comatus
Shaggy Mane / Shaggy Ink Cap
For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.
Research areas: Glucose & Metabolic Research, Cellular & Immune Studies, Immunological Research
Research overview
Historical use
Eaten as a culinary mushroom in Europe and North America, known as the shaggy ink cap. Not historically prominent in TCM but used in Chinese folk medicine under the name 'Ji Tui Mo'. Recognised for its edibility (must be consumed promptly after harvest as it auto-digests rapidly). Traditional use in Chinese folk medicine for improved digestion and energy.
Modern research context
Studied primarily for antidiabetic properties; ethanolic extracts demonstrate significant hypoglycaemic and antioxidant activity in animal models [1][3]. Mycelium polysaccharides have shown anti-diabetic nephropathic activity in preclinical studies [4]. A comprehensive review documents both the functional properties and potential safety concerns — including a disulfiram-like reaction with alcohol mediated by coprine [2]. Anti-inflammatory and antiarthritic properties are under early investigation via nanogel formulations [5].
Adverse effects
Well tolerated when consumed cooked, with rare GI symptoms reported. Coprine (found in related Coprinus species — notably C. atramentarius, NOT C. comatus) causes a disulfiram-like reaction with alcohol; this compound is absent in C. comatus. Species identification is critical — do not confuse with related species.
Contraindications
Species confusion risk (C. atramentarius contains coprine — disulfiram-like reaction with alcohol). C. comatus itself does not contain coprine. Antidiabetic drugs — potential additive hypoglycaemia. No other established contraindications.
Clinical and phytochemical data
Used part
Fruiting body
Primary active compounds
Coprinus comatus polysaccharides (CCP — beta-glucans)
Vanadium (insulin-mimetic mineral trace element)
Coprinin (lectin)
Ergothioneine
Phenolic compounds
Mechanism of action
Polysaccharides stimulate insulin secretion from pancreatic beta-cells and improve insulin sensitivity via PPAR-γ activation; inhibit α-glucosidase and aldose reductase. Lectins act as TLR-4 agonists, promoting macrophage activation. Ink-cap polysaccharides upregulate Nrf2/HO-1, providing antioxidant protection in hyperglycaemic conditions. Coprinol exhibits antimicrobial activity against MRSA.
Pharmacokinetics
Absorption
Absorption is compound-dependent. L-ergothioneine, found in Coprinus comatus, is avidly absorbed after oral administration in healthy humans, producing significant and sustained elevations in plasma and whole blood concentrations [1]. No human oral absorption data exist for vanadium, coprinin, or the beta-glucan fractions — No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Vanadium absorption: 0.5–2% of oral dose; accumulates in bone, liver, kidney. Polysaccharide fractions: limited systemic absorption, active at mucosal level. Human PK data for whole extract unavailable.
Distribution
L-ergothioneine distributes extensively to whole blood and erythrocytes in humans via the OCTN1 transporter [1]. Vanadium pharmacokinetics in humans were studied following intravenous exposure; the metal distributes rapidly to erythrocytes and bone, with a multi-compartment disposition profile [2]. Oral vanadium distribution data are not available. No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Polysaccharide fractions concentrate at GALT, pancreatic tissue, and spleen, consistent with antidiabetic and immunomodulatory activity. Vanadium-containing compounds (if present) distribute to bone and kidney. No formal human pharmacokinetic distribution data available for this species.
Metabolism
L-ergothioneine is partially biotransformed in humans to hercynine and S-methyl-ergothioneine, as confirmed by whole blood measurements after oral dosing [1]. No human metabolic data exist for vanadium (oral) or other Coprinus constituents — No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Vanadium: reduction from V(V) to V(IV) in gut; hepatic metabolism. Polysaccharides: gut microbial fermentation.
Excretion
L-ergothioneine is strongly retained by the body; urinary excretion is less than 4% of the administered oral dose in healthy humans [1]. Vanadium is excreted renally following IV exposure in humans, with a terminal half-life of several days due to bone sequestration [2]. No oral excretion data for vanadium in a dietary context are available — No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Vanadium: primarily renal; polysaccharides: fecal.
Safety and interactions
Drug interactions
Lack of clinical studies prevents interaction grading. Unknown safety profile with concomitant drug use.
Toxicity
LD50 of whole extract >5 g/kg (oral, rodents). Vanadium toxicity: high doses (not achievable from dietary mushroom) cause GI irritation, renal accumulation; irrelevant at culinary quantities. No clinically significant organ toxicity documented.
Special precautions
Pregnancy
Insufficient data on concentrated extracts. Dietary consumption likely safe. Vanadium at pharmacological doses is not recommended in pregnancy.
Lactation
No data on breast milk excretion. Dietary consumption likely safe; concentrated extracts — insufficient data.
Hepatic impairment
No hepatotoxicity documented. Standard monitoring recommended.
Renal impairment
Vanadium excreted renally; accumulation possible in renal impairment. Avoid high-dose concentrated preparations in renal failure.
Sources and references
- [1] - Ratnaningtyas NI., "Ethanol extract of the mushroom Coprinus comatus exhibits antidiabetic and antioxidant activities in streptozotocin-induced diabetic rats.", Pharm Biol, 2022, PMID: 35675226
- [2] - Nowakowski P., "The two faces of Coprinus comatus-Functional properties and potential hazards.", Phytother Res, 2020, PMID: 32462723
- [3] - Husen F., "Antidiabetic Effects and Antioxidant Properties of the Saggy Ink Cap Medicinal Mushroom, Coprinus comatus.", Int J Med Mushrooms, 2021, PMID: 34595888
- [4] - Gao Z., "Characterization and anti-diabetic nephropathic ability of mycelium polysaccharides from Coprinus comatus.", Carbohydr Polym, 2021, PMID: 33142624
- [5] - Ratnaningtyas NI., "Therapeutic potential of Coprinus comatus nanogels: Antiarthritic and anti-inflammatory effects in Freund's adjuvant-induced arthritis.", Vet World, 2025, PMID: 40342737